Indications for starting Statins in hyperlipidemia n doses.
Reading File
Finding Sources
Finding Sources
Searching PubMed
statins AND primary prevention
Searching the Web
2026 ACC AHA guideline statin therapy primary prevention LDL 190 diabetes intensity dosing
Quick answer
Indications for starting a statin
Use lifestyle measures for everyone, but start statin therapy when ASCVD risk or LDL-C level makes drug treatment beneficial.
| Clinical setting | Recommended statin approach |
|---|---|
| Clinical ASCVD: prior MI/ACS, angina, coronary or peripheral revascularization, ischemic stroke/TIA, PAD | High-intensity statin if age ≤75 years and tolerated. For age >75, moderate or high intensity after individual discussion. |
| LDL-C ≥190 mg/dL (≥4.9 mmol/L), age 20-75 | High-intensity statin, regardless of calculated 10-year risk. |
| Diabetes mellitus, age 40-75, LDL-C 70-189 mg/dL | At least moderate-intensity statin. Use high intensity if multiple ASCVD risk factors, age 50-75, or high estimated risk. |
| No diabetes, age 40-75, LDL-C 70-189 mg/dL | Calculate 10-year ASCVD risk: ≥20%: high intensity; 7.5% to <20%: moderate intensity; 5% to <7.5%: consider moderate intensity if risk enhancers; <5%: lifestyle usually sufficient. |
| Age 20-39 | Consider statin if LDL-C ≥160 mg/dL plus strong family history of premature ASCVD or other major risk enhancers. |
| Chronic kidney disease, inflammatory disorders, HIV, premature menopause/preeclampsia, high Lp(a), persistent TG ≥175 mg/dL, strong family history | These are “risk enhancers” that favor starting or intensifying a statin when risk is borderline/intermediate. |
| Coronary artery calcium (CAC), when decision uncertain | CAC = 0 may support deferring in selected people; CAC 1-99 favors statin, especially age ≥55; CAC ≥100 or ≥75th percentile supports statin. |
Risk-enhancing factors include family history of premature ASCVD, metabolic syndrome, CKD, chronic inflammatory disease, South Asian ancestry, persistently elevated triglycerides, elevated apoB, Lp(a), or hs-CRP.
Statin doses and intensity
| Intensity | Expected LDL-C reduction | Drugs and daily doses |
|---|---|---|
| High intensity | ≥50% | Atorvastatin 40-80 mg; Rosuvastatin 20-40 mg |
| Moderate intensity | 30% to 49% | Atorvastatin 10-20 mg; Rosuvastatin 5-10 mg; Simvastatin 20-40 mg; Pravastatin 40-80 mg; Lovastatin 40-80 mg; Fluvastatin XL 80 mg or 40 mg twice daily; Pitavastatin 1-4 mg |
| Low intensity | <30% | Simvastatin 10 mg; Pravastatin 10-20 mg; Lovastatin 20 mg; Fluvastatin 20-40 mg; Pitavastatin 1 mg |
Practical prescribing points
- Obtain a baseline lipid panel, ALT, assess diabetes risk and drug interactions. CK is not routinely needed unless there is a history of muscle disease/symptoms.
- Recheck lipids about 4-12 weeks after starting or changing dose, then every 3-12 months.
- Aim for ≥50% LDL-C reduction with high-intensity treatment and 30%-49% reduction with moderate intensity.
- In pregnancy, statins are generally avoided.
- If muscle symptoms occur, stop temporarily, exclude other causes, then retry a lower dose or a different statin. Doubling a statin dose produces only about an additional 6% LDL-C reduction, so switching or adding non-statin therapy may be preferable when needed.
Textbook support: Goldman-Cecil Medicine, “Indications for Statins,” and Harrison’s Principles of Internal Medicine, “Hyperlipidemia.”
This is a shared conversation. Sign in to Orris to start your own chat.